Regulatory science plays a critical role in balancing innovation, patient safety, and timely access to medicines. Despite its importance, little is known about how global research in this field has evolved. This study conducted a comprehensive bibliometric analysis of 20,371 publications indexed between 2005 and April 2025 across PubMed, Scopus, Web of Science, and ScienceDirect. Using Biblometrix in R, VOSviewer, and SciVal, the study explored publication trends, thematic evolution, collaboration networks, and citation impact. The results demonstrate consistent growth in regulatory science research over the past two decades. Core themes such as pharmacovigilance, drug safety, and clinical trials remain central, while newer areas including biosimilars, real-world evidence, and advanced therapies have gained prominence in response to technological advances and changing healthcare needs. Leading contributions originate from institutions such as INSERM, the FDA, and Harvard University, and countries including the United States, United Kingdom, and France. However, low- and middle-income countries remain underrepresented, despite their increasing importance in clinical trials and pharmaceutical supply chains. The findings highlight both progress and gaps in the field, emphasizing the need for greater inclusivity, regulatory harmonization, and capacity-building to strengthen global regulatory systems.
George BS, Jaganathan J, Jaganathan Y, Girivasan SN, Vishwanathan B, Sivasankaran P. A global bibliometric analysis of regulatory science in the pharmaceutical industry. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2026.262045
1. Grabowski HG. Public policy and pharmaceutical innovation. Health Care Financ Rev. 1982;4(1):75–87.
2. Pan GJD, Lindquist M, Gelperin K. Post marketing spontaneous pharmacovigilance reporting systems. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology, 5th ed. Hoboken, NJ: Wiley-Blackwell; 2012, pp: 135–57. doi: https://doi.org/10.1002/9781119959946.ch10
3. Eichler HG, Bloechl-Daum B, Broich K, Kyrle PA, Oderkirk J, Rasi G, et al. Data rich, information poor: can we use electronic health records to create a learning healthcare system for pharmaceuticals?. Clin Pharmacol Ther. 2019;105(4):912–22. doi: https://doi.org/10.1002/cpt.1226
4. Arden NS, Fisher AC, Tyner K, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: preparing for the smart factories of the future. Int J Pharm. 2021;602:120554. doi: https://doi.org/10.1016/j.ijpharm.2021.120554
5. Roth L, Bempong D, Babigumira JB, Banoo S, Cooke E, Jeffreys D, et al. Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems. Glob Health. 2018;14(1):102. doi: https://doi.org/10.1186/s12992-018-0421-2
6. Passas I. Bibliometric analysis: the main steps. Encyclopedia. 2024;4(2):1014–25. doi: https://doi.org/10.3390/encyclopedia4020065
7. Öztürk O, Kocaman R, Kanbach DK. How to design bibliometric research: an overview and a framework proposal. Rev Manag Sci. 2024;18(11):3333–461. doi: https://doi.org/10.1007/s11846-024- 00738-0
8. Bornmann L, Leydesdorff L. Scientometrics in a changing research landscape: bibliometrics has become an integral part of research quality evaluation and has been changing the practice of research. EMBO Rep. 2014;15(12):1228–32. doi: https://doi.org/10.15252/embr.201439608
9. Dinda AK. Regulatory science: the need for empowering Indian innovation. Indian J Med Res. 2021;154(6):770–5. doi: https://doi.org/10.4103/ijmr.IJMR_1665_19
10. Aronson JK. Something new every day: defining innovation and innovativeness in drug therapy. J Ambulat Care Manage. 2008;31(1):65–8. doi: https://doi.org/10.1097/01. jac.0000304100.38120.b2
11. Zhang J, Tang S, Sun P. From command-control to lifecycle regulation: balancing innovation and safety in China’s pharmaceutical legislation. Healthcare. 2025;13(6):588. doi: https://doi.org/10.3390/healthcare13060588
12. Wang B, Liu J, Kesselheim AS. Variations in time of market exclusivity among top-selling prescription drugs in the United States. JAMA Intern Med. 2015;175(4):635–7. doi: https://doi.org/10.1001/jamainternmed.2014.7968
13. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, De Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet Lond Engl. 2017;389(10067):403–76. doi: https://doi.org/10.1016/S0140-6736(16)31599-9
14. Pisani E, Nistor AL, Hasnida A, Parmaksiz K, Xu J, Kok MO. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania. Wellcome Open Res. 2019;4:70. doi: https://doi.org/10.12688/wellcomeopenres.15236.1
15. Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Netw Open. 2018;1(4):e181662. doi: https://doi.org/10.1001/jamanetworkopen.2018.1662
16. Iglesias-Lopez C, Agustí A, Obach M, Vallano A. Regulatory framework for advanced therapy medicinal products in Europe and United States [Internet]. Front Pharmacol Internet. 2019;10:921. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00921/full
17. Bolislis WR, De Lucia ML, Dolz F, Mo R, Nagaoka M, Rodriguez H, et al. Regulatory agilities in the time of COVID-19: overview, trends, and opportunities. Clin Ther. 2021;43(1):124–39. doi: https://doi.org/10.1016/j.clinthera.2020.11.015
18. Tirupakuzhi Vijayaraghavan BK, Gupta E, Ramakrishnan N, Beane A, Haniffa R, Lone N, et al. Barriers and facilitators to the conduct of critical care research in low and lower-middle income countries: a scoping review. PLoS One. 2022;17(5):266836. doi: https://doi.org/10.1371/journal.pone.0266836
19. Pushparajah DS. Making patient engagement a reality. Patient. 2018;11(1):1–8. doi: https://doi.org/10.1007/s40271-017-0264-6
20. Weisfeld V, Lustig TA, Forum on Drug Discovery D, Policy B on HS, Medicine (IOM) I of. Characteristics of Harmonized Regulations and Regulatory Structures. In: International Regulatory Harmonization Amid Globalization of Drug Development: Workshop Summary [Internet]. National Academies Press (US); 2013 [cited 2025 May 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK174221/
21. Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. J Young Pharm JYP. 2010;2(3):315–20. doi: https://doi.org/10.4103/0975-1483.66802
22. Eichler HG, Kossmeier M, Zeitlinger M, Schwarzer-Daum B. Orphan drugs’ clinical uncertainty and prices: addressing allocative and technical inefficiencies in orphan drug reimbursement. Front Pharmacol. 2023;14:1074512. doi: https://doi.org/10.3389/fphar.2023.1074512
23. Hennessy S, Atsuta Y, Hill S, Rägo L, Juhaeri J.Real-world data and real-world evidence in regulatory decision making: report summary from the council for International Organizations of Medical Sciences (CIOMS) working group XIII. Pharmacoepidemiol Drug Saf. 2025;34(3):e70117. doi: https://doi.org/10.1002/pds.70117
24. Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491–509. doi: https://doi.org/10.1111/bcp.15193
25. Chejor P, Dorji T, Dema N, Stafford A. Good manufacturing practice in low- and middle-income countries: challenges and solutions for compliance. Public Health Chall. 2024;3(1):158. doi: https://doi.org/10.1002/puh2.158
26. Raj N, Fernandes S, Charyulu NR, Dubey A, G. S. R, Hebbar S. Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Ther Adv Drug Saf. 2019;10:2042098619865413. doi: https://doi.org/10.1177/2042098619865413
27. Corrigan-Curay J, Sacks L, Woodcock J.Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867–8. doi: https://doi.org/10.1001/jama.2018.10136
28. Anklam E, Bahl MI, Ball R, Beger RD, Cohen J, Fitzpatrick S, et al. Emerging technologies and their impact on regulatory science. Exp Biol Med. 2022;247(1):1–75. doi: https://doi.org/10.1177/15353702211052280
29. Wang J, Frietsch R, Neuhäusler P, Hooi R. International collaboration leading to high citations: global impact or home country effect?. J Informetr. 2024;18(4):101565. doi: https://doi.org/10.1016/j.joi.2024.101565
30. Austin CP. Opportunities and challenges in translational science. Clin Transl Sci. 2021;14(5):1629–47. doi: https://doi.org/10.1111/cts.13055
31. Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49(6):929–39. doi: https://doi.org/10.1177/2168479015580384
32. Olsson S. Pharmacovigilance training with focus on India. Indian J Pharmacol. 2008;40:S28–30.
33. Garashi HY, Steinke DT, Schafheutle EI. A systematic review of pharmacovigilance systems in developing countries using the WHO pharmacovigilance indicators. Ther Innov Regul Sci. 2022;56(5):717–43. doi: https://doi.org/10.1007/s43441-022-00415-y
34. Khadem Broojerdi A, Baran Sillo H, Ostad Ali Dehaghi R, Ward M, Refaat M, Parry J.The World Health Organization global benchmarking tool an instrument to strengthen medical products regulation and promote universal health coverage. Front Med. 2020;7:457. doi: https://doi.org/10.3389/fmed.2020.00457
Year
Month